

# SUBJECT INDEX

## A

Acquired immune deficiency syndrome

Burkitt lymphoma and, 258-59

CD4 molecule and, 562

human cytomegalovirus and, 289

human immunodeficiency virus and, 574-77

retroviruses and, 320

Actin polymerization

iC3b receptor deficiency and, 132

neutrophil chemotactic receptors and, 128-29

Acute nonlymphoblastic leukemia

bone marrow transplantation and, 54

Adenosine deaminase deficiency severe combined immunodeficiency and, 639

Adenoviruses

host range of, 306

Adenylate cyclase

activation of, 179

adrenergic receptors and, 626, 641

autacoids and, 625

histamine and, 649-50

insulin and, 636

prostaglandin E<sub>2</sub> and, 644

Adrenaline

See Epinephrine

Adrenergic receptors, 641-42

adenylate cyclase and, 626, 641

affinity states of, 624-25

catecholamines and, 179

epinephrine and, 627

Adrenocorticotrophic hormone

glucocorticoids and, 633

receptors for, 634

Adriamycin

immunotargeting of, 17

Adult respiratory distress syndrome

neutrophil activation and, 132

Adult T-cell leukemia, 541-42

development of, 553-55

interleukin-2 receptor and, 551-52, 554

Alanine

experimental allergic encephalomyelitis and, 16

polymerization on macromolecules, 11

Albinism

oculo-cutaneous

Chediak-Higashi syndrome and, 135

Alkaline phosphatase

neutrophil granules and, 133

Allergy

eicosapentaenoic acid and, 67

lipoxigenases and, 67

Allograft rejection

glucocorticoids and, 633

Amino acids

polymers of, 2

D-Amino acids

polymers of

immunogenicity of, 6-7

4-Aminopyridine

plasma membrane and, 185-86

Ammonium chloride

antigen processing and, 480

Anaphylaxis

lipoxigenase products and, 73

Anemia

hemolytic

T suppressor cells and, 101

Ankylosing spondylitis, 11

Antibodies, 11-13

adrenocorticotrophic hormone and, 634

antibacterial

autoantibodies and, 100-1

anti-CD3, 518-19

anti-DNA, 88-89, 91, 95-102

anti-thyocyte

T suppressor cells and, 101

anti-idiotypic

rheumatoid factor and, 121

anti-immunoglobulin

B-cell activation and, 175

calcium mobilization and, 184-86

phosphatidylinositol

metabolic cycle and, 182

antiphosphorylcholine, 99

anti-thyroglobulin

B cells and, 92

immunoglobulin

anti-DNA, 99

autoantigens and, 87

complement and, 116

differentiation of, 96

pathogenicity of, 92

somatic mutation of, 86

T-cell antigen receptor and, 509-12

virus infectivity and, 312

Anti-thyocyte antibodies

T suppressor cells and, 101

Antigenicity

molecular basis of, 6

peptide length and, 484-85

Antigens

B-cell activation and, 175-76

CD2, 237-43

cross-reacting

autoantibodies and, 102

la interactions of, 488-92

leukocyte adherence-related, 130

lymphocyte function-

associated, 130, 225-43

T-cell function and, 521

major histocompatibility complex

thymic stroma and, 339

Mo1, 130

phosphatidylinositol metabolism and, 182

protein

T-cell responses to, 492-94

synthetic, 5-8

T cells and, 461-73

viral

autoreactivity of, 102

xenogenic

autoimmunity and, 102

Antithrombin III, 28

Antithyroglobulin antibodies

B cells and, 92

$\alpha$ -1-Antitrypsin, 28

Aplastic anemia

bone marrow transplantation and, 45, 51-53

Arachidonate

metabolites of, 65-68

Arachidonic acid

lipoxigenation of

interleukins and, 75

phospholipase C and, 78

- Arachidonic acid metabolism, 65-68  
 leukotriene B<sub>4</sub> and, 642  
 lipocortin and, 630  
 prostaglandin E<sub>2</sub> and, 644
- Arginine vasopressin  
 lymphocyte receptors for, 635
- Arsanil-trityrosine  
 immune response and, 6
- Arthritis  
 rheumatoid, 94, 109  
   indomethacin and, 648  
   rheumatoid factor and, 119-22
- Ascorbate  
 Chediak-Higashi syndrome and, 135-36
- Aspartate transcarbamylase  
 structure of, 30
- Aspergillus*  
 chronic granulomatous disease and, 141
- Asthma  
 adrenergic hyporesponsiveness in, 641-42
- Atropine  
 natural killer cells and, 639
- Autacoids  
 homeostasis and, 622-23  
 immune response and, 627  
 lymphocyte receptors for, 621-22
- Autoantibodies  
 antibacterial antibodies and, 100-1  
 autoimmune disease and, 87-88  
 cross-reacting antigens and, 102  
 derivation of, 90-94  
 formation of  
   somatic mutation and, 94-102  
   genetic origins of, 93  
   natural, 87-88, 91-92  
   normal antibodies and, 88  
   pathogenic  
     genes encoding, 87  
     rheumatoid factor, 109-23  
 T suppressor cells and, 101
- Autoantigens  
 IgM antibodies and, 87
- Autoimmune disease  
 autoantibodies and, 87-88  
 eicosapentaenoic acid and, 67  
 glucocorticoids and, 633  
 rheumatoid factor and, 118-22
- Autoimmune genes, 87-90
- Autoimmune response  
 T cells and, 95
- Autoimmunity  
 motheaten mice and, 373
- somatic mutation in, 85-102  
 systemic  
   immunodeficiency and, 378-80  
   xenogenic antigens and, 102
- Azoproteins  
 synthetic models for, 5
- Azuophil granules  
 neutrophil maturation and, 132
- B**
- Basophils  
 histamine release by, 648-49  
 cyclic AMP agonists and, 627  
 leukotriene B<sub>4</sub> and, 68  
 5-lipoxygenase products of, 68
- B-cell activating factor  
 B-cell activation and, 175-76
- B-cell antigen receptor, 331, 477  
 transmembrane signaling by, 182-91
- B-cell epitopes, 494-96
- B-cell growth factor  
 dibutyryl cyclic AMP and, 629
- B-cell lymphoma  
 bone marrow transplantation and, 117-18  
 Sjogren's syndrome and, 119
- B-cell neoplasms  
 chromosome translocations in, 254-59
- B cells  
 adrenocorticotrophic hormone and, 634  
 anti-DNA antibodies and, 95  
 antigen recognition by, 514-15  
 antithyroglobulin antibodies and, 92  
 B-cell stimulatory factor-1 and, 439-43  
 cyclic AMP and, 626  
 cyclic AMP agonists and, 628-29  
 Epstein-Barr virus-transformed LFA-1 antigen on, 130  
 histamine receptors on, 649  
 Ia-binding ligands and, 191  
 immune regulation and, 176-78  
 immunoglobulin and, 503  
 immunoglobulin gene expression and, 151-52  
 insulin and, 637  
 γ-interferon and, 191  
 interleukin-4 and, 190-91
- leukocyte adhesion deficiency disease and, 229-30
- LFA-1 surface sites on, 225
- lipopolysaccharide and, 190
- measles virus and, 283-87
- natural autoantibodies and, 87, 90, 92-93
- neoplastic transformation of, 117  
 Sjogren's syndrome and, 119
- permeability of, 190
- rheumatoid factor synthesis and, 114-15
- severe combined immune deficiency and, 370-71
- substance P receptors on, 636
- T helper cells and, 177
- transgene expression in, 154
- transmembrane signaling in, 175-93
- B-cell stimulatory factor-1, 429-55  
 cDNA clones for, 432-34  
 hematopoietic cells and, 452-54  
 high-affinity receptors for, 434-39  
 immunoglobulins G and E and, 443-47  
 production of, 450-51  
 purification and characterization of, 429-32  
 resting B cells and, 439-43  
 T cell-B cell interactions and, 451-52  
 T cells and, 447-50
- B-cell tumors  
 autoantibodies and, 91
- Bone marrow  
 pre-T cells in, 351-52
- Bone marrow transplantation, 43-59  
 aplastic anemia and, 51-53  
 B-cell lymphoma and, 117-18  
 human leukocyte antigen system and, 45-47  
 iC3b receptor deficiency and, 131  
 immunodeficiency disease and, 48-51  
 leukemia and, 53-58  
 leukocyte adhesion deficiency disease and, 230-31  
 mismatched  
   treatment for, 47-48  
 osteopetrosis and, 391
- Bordetella pertussis*  
 leukocyte adhesion deficiency disease and, 230

- Bordetella pertussis* toxin  
neutrophil chemotactic receptors and, 128
- Bovine papilloma virus  
host range of, 306
- Brain abscess  
chronic granulomatous disease and, 141
- Burkitt lymphoma  
acquired immune deficiency syndrome and, 258-59  
chromosome translocations in, 254-55  
*c-myc* gene and, 256  
sporadic vs. endemic, 257-58
- C
- Calcium  
anti-immunoglobulin antibodies and, 184-86  
exocytosis and, 138  
inositol lipid metabolism and, 180  
neutrophil chemotaxis and, 129  
protein kinases and, 179  
as second messenger, 625
- Calmodulin  
protein kinases and, 179
- Cancer  
chromosome translocations and, 253-73  
immunotoxins and, 17  
T-cell antigen receptor genes and, 608-10
- Candida*  
chronic granulomatous disease and, 141  
myeloperoxidase deficiency and, 144
- Candida albicans*  
phagolysosomal fusion and, 139
- Candidiasis  
mucocutaneous  
cimetidine and, 654
- Carbohydrate  
complement C1-inhibitor and, 27  
complement C1q and, 23  
N-Carboxyamino acid anhydrides  
polymerization of, 2-3
- Carcinoembryonic antigen, 14
- Carcinoma  
hepatocellular  
hepatitis B virus and, 313
- Cardiolipin  
anti-DNA antibodies and, 97, 102
- Catecholamines  
adrenergic receptors and, 179
- Cathepsin G  
Chediak-Higashi syndrome and, 135
- Cell adhesion molecules, 223-44
- Cell aggregation  
leukotriene B<sub>4</sub> and, 69
- Cell-mediated immunity  
cytotoxic T cells and, 312-13  
vaccinia virus and, 306  
virus infection and, 312-13
- Cell metabolism  
protein kinases and, 179
- Cellulitis  
hyperimmunoglobulin E syndrome and, 136
- Chediak-Higashi syndrome, 135-36, 382
- Chemotaxis  
leukotriene B<sub>4</sub> and, 69-70
- Chlamydia*  
phagolysosomal fusion and, 139
- Chloroquine  
antigen processing and, 480
- Cholera toxin, 14-15  
glucocorticoids and, 629  
plaque-forming cells and, 629
- Cholesterol  
lipoxygenase products and, 79
- Chromatography  
B-cell stimulatory factor-1 and, 430
- Chromosome 14  
T-cell neoplasia and, 255
- Chromosome translocation  
cancer and, 253-73  
chronic myelogenous leukemia and, 271-72  
mechanisms for, 259-67  
multiple  
leukemia and, 272-73  
properties of, 254-59  
T-cell antigen receptor genes and, 610-13
- Chronic granulomatous disease, 141-44
- Chronic lymphatic leukemia  
rheumatoid factor and, 116-17
- Chronic lymphocytic leukemia  
chromosome translocation and, 259-60
- Chronic myelogenous leukemia  
bone marrow transplantation and, 55, 57  
chromosome translocation and, 271-72  
Philadelphia chromosome and, 253
- Cimetidine  
immune response and, 654
- T suppressor cells and, 654
- Clonal selection theory, 8
- Cobra venom  
lipoxygenase pathway and, 68
- Complement  
immunoglobulin antibodies and, 116  
lipoxygenase product formation and, 68
- Complement C1  
activation of  
immune complex-induced, 33-35  
models for, 36-38  
spontaneous, 31-33
- Complement C1 complex  
structure of, 28-31
- Complement C1-inhibitor  
hereditary angioedema and, 32-33  
structure of, 27-28
- Complement C1q  
atomic resolution model for, 22-24  
immunoglobulin M and, 34  
structure of, 22
- Complement C1r<sub>2</sub>  
structure of, 24-25
- Complement C1r<sub>2</sub>C1s<sub>2</sub>  
structure of, 25-27
- Complement C1s  
structure of, 25
- Complement cascade  
neutrophil granules and, 132-33
- Complement deficiency, 377-78
- Cowpox, 306
- Cranial nerve palsy  
Chediak-Higashi syndrome and, 135
- Cryoglobulinemia  
mixed  
rheumatoid factor and, 119
- Cyclic AMP  
adenylate cyclase and, 625  
B cells and, 626  
Chediak-Higashi syndrome and, 135-36  
epinephrine and, 178  
immune response and, 627-29  
prostaglandin E<sub>2</sub> and, 644  
protein kinases and, 179  
T suppressor cells and, 626
- Cyclic GMP  
cellular levels of  
regulation of, 179  
protein kinases and, 179  
as second messenger, 625
- Cyclooxygenase pathway  
arachidonic acid and, 65-68
- Cyclooxygenase products  
lipocortin and, 630

- Cyclophosphamide  
  immunosuppression and, 49,  
  51
- Cyclosporin A  
  B-cell stimulatory factor-1  
  and, 441
- Cyclosporine  
  bone marrow transplantation  
  and, 57
- Cytochalasins  
  exocytosis and, 138
- Cytochrome *b*  
  azurophil granules and, 132-  
  33  
  chronic granulomatous disease  
  and, 142-43
- Cytochrome *c*  
  antigenic sites on, 481  
  MHC class II-restricted T  
  cells and, 478
- Cytokines  
  B-cell function and, 176
- Cytotoxicity  
  LFA-1 and, 226
- Cytotoxic T cells  
  adenosine and, 640  
  anti-CD2 antibodies and, 521  
  anti-CD3 antibodies and, 519  
  anti-LFA-1 antibodies and,  
  521  
  cell-mediated immunity and,  
  312-13  
  cholinergic agonists and, 638-  
  39  
  cyclic AMP agonists and,  
  627-28  
  glucocorticoids and, 630-32  
  growth hormone and, 635  
  herpes simplex virus and, 317  
  histamine and, 653  
  influenza virus and, 318  
  insulin and, 637  
  leukotriene B<sub>4</sub> and, 643  
  MHC class I-restricted, 478  
  motheaten mice and, 372  
  murine leukemia virus and,  
  320  
  planar membranes and, 465  
  receptors on, 462  
  vesicular stomatitis virus and,  
  319
- D
- Daunomycin  
  immunotargeting of, 17
- Dephosphorylation  
  proteins and, 178-79
- Diabetes mellitus  
  lymphocyte insulin receptors  
  and, 637  
  myeloperoxidase deficiency  
  and, 144
- Diacylglycerol  
  anti-immunoglobulin antibod-  
  ies and, 182-83  
  B-cell activation and, 176  
  membrane depolarization and,  
  188  
  protein kinase C and, 180-81,  
  520  
  as second messenger, 625
- Diapedesis  
  neutrophils and, 128, 132
- DiGeorge syndrome, 369
- Diisopropylfluorophosphate  
  complement C1s and, 36
- Dimaprit  
  lymphocytes and, 650
- Dinitrophenyl-hexalysine  
  immune response and, 6
- Diphtheria toxin  
  leukocyte adhesion deficiency  
  disease and, 230
- DNA  
  complement C1 and, 35, 37
- DNA clones  
  B-cell stimulatory factor-1  
  and, 432-34
- DNA hybridization  
  recombinant viruses and, 308
- DNA synthesis  
  B-cell stimulatory factor-1  
  and, 454  
  lipooxygenase products and,  
  70-71
- Drugs  
  immunotargeting of, 16-17
- Dystrophia muscularis, 388
- E
- Eczema  
  hyperimmunoglobulin E syn-  
  drome and, 136
- Eicosapentaenoic acid  
  leukotriene metabolism and,  
  67
- Eicosatetraenoic acid  
  DNA synthesis and, 70
- Elastase  
  Chediak-Higashi syndrome  
  and, 135
- Encephalomyelitis  
  experimental allergic, 15-16
- Enderoperoxides  
  cyclooxygenase pathway and,  
  68
- Endocarditis  
  subacute bacterial  
  rheumatoid factor and, 119
- Endocytosis  
  B-cell stimulatory factor-1 re-  
  ceptor and, 437
- Endoglycosidase F
- B-cell stimulatory factor-1  
  and, 430, 433
- Endorphin  
  lymphocyte receptors for, 634
- Endothelial cells  
  histamine and, 649  
  neutrophil adherence and, 132
- Endotoxin  
  neutrophil adherence and, 132
- Enkephalin  
  lymphocyte receptors for, 634
- Eosinophils  
  leukotriene B<sub>4</sub> and, 69  
  5-lipoxygenase products of,  
  68  
  respiratory burst in, 139
- Epidermal growth factor recep-  
  tors  
  protein kinases and, 180
- Epinephrine  
  adrenergic receptors and, 627  
  cyclic AMP and, 178
- Epithelial cells  
  15-lipoxygenase products in,  
  77
- Epitopes  
  antigenic specificity of  
  electrical charge and, 6  
  B-cell, 494-96  
  T-cell  
  identification of, 481-82  
  models for, 485-87  
  primary amino acid sequ-  
  ences of, 479-81  
  size of, 482-84  
  structure of, 477-97
- Epstein-Barr virus  
  chromosome translocation  
  and, 248  
  human cytomegalovirus and,  
  289  
  rheumatoid factor synthesis  
  and, 114-15  
  surface glycoprotein of, 320
- Erythrocytes  
  antibody-coated  
  complement C1 and, 35
- Erythrocyte sedimentation rate  
  chronic granulomatous disease  
  and, 141
- Erythroid precursor cells  
  LFA-1 on, 225
- Estrogen, 624
- Experimental allergic enceph-  
  alomyelitis, 15-16
- Experimental autoimmune thyr-  
  oiditis, 91
- F
- Feline leukemia virus  
  lymphocyte proliferation and,  
  287

- Fluorescence spectroscopy  
  T cell antigen recognition  
    and, 468-70
- Foot-and-mouth disease, 15
- Formyl peptides  
  inflammatory response and,  
    141
- Fucoidin  
  lymphocyte migration and,  
    209
- Furunculosis  
  hyperimmunoglobulin E syn-  
    drome and, 136
- G
- Gastroenteritis virus of swine  
  spike glycoprotein of, 320
- Gelatin  
  antigenicity of, 5-6
- Gel electrophoresis  
  B-cell stimulatory factor-I  
    and, 430
- Gelsolin  
  neutrophil granules and, 138
- Genes  
  autoimmune, 87-90  
  CD4, 561-79  
    evolution of, 577-79  
    isolation of, 565-67  
    structure of, 573-74  
  CD8, 561-79  
    evolution of, 577-79  
    isolation of, 565-67  
    structure of, 567-73  
  T-cell antigen receptor, 585-  
    613
- Gingivitis  
  iC3b receptor deficiency and,  
    130
- Gladiin  
  poly-DL-alanylation and, 12
- Glucocorticoids  
  adrenergic receptors and, 642  
  anti-inflammatory action of,  
    78  
  cholera toxin and, 629  
  cyclooxygenase pathways and,  
    647  
  lymphocyte receptors for,  
    629-33
- Glucose-6-phosphate de-  
  hydrogenase deficiency  
  chronic granulomatous disease  
    and, 143-44
- Glutamic acid  
  experimental allergic encephalo-  
    myelitis and, 16
- Glutaraldehyde  
  antigen processing and, 480
- Glutathione  
  slow-reacting substances and,  
    72
- Glycolipids  
  antigens specific to, 6
- Glycoproteins  
  CD4  
    function of, 562-65  
  CD8  
    function of, 562-65
- Glycosidase  
  lymphocyte migration and,  
    209
- Glycosylation-inhibiting factor  
  I-J antibodies and, 421  
  lipocortin and, 630
- Graft-versus-host disease, 43-44,  
  48-59
- Granulocytes  
  B-cell stimulatory factor-I  
    and, 429  
  LFA-1 and, 226  
  5-lipoxygenase products and,  
    76
- Guanine nucleotide binding pro-  
  teins  
  adenylate cyclase and, 179
- Guanylate cyclase  
  insulin and, 636
- H
- Hairy T-cell leukemia  
  human T-cell leukemia virus  
    type 2 and, 542-43
- Haptens  
  antigens specific to, 6  
  DNP-specific IgA myeloma  
    and, 12
- Helper T cells  
  See T helper cells
- Hemolytic anemia  
  T suppressor cells and, 101
- Hemolytic complement de-  
  ficiency, 377-78
- Heparin  
  complement C1 and, 35, 37
- Hepatitis  
  glucocorticoids and, 633
- Hepatitis B, 15
- Hepatitis B virus, 313-16  
  recombinant viruses and, 316
- Hepatocellular carcinoma  
  hepatitis B virus and, 313
- Hepatoma, 17
- Hereditary angioedema  
  complement C1-inhibitor and,  
    32-33
- Herpes simplex virus  
  genetic engineering and, 306  
  recombinant viruses and, 317
- Herpesvirus  
  human cytomegalovirus and,  
    289
- Hexose monophosphate shunt  
  phagocytic cells and, 139-40
- High endothelial cell venules  
  lymphocyte recirculation and,  
    205-17
- Histamine  
  arachidonic acid metabolism  
    and, 72  
  H1 receptors and, 627  
  immune response and, 627  
  lymphocyte receptors for,  
    648-55  
  T cell-derived lymphokines  
    and, 655
- Histamine cell stimulatory factor  
  histamine synthesis and, 655
- Histamine-induced suppressor  
  factor, 652-53
- Histidine, 9
- Histidine decarboxylase  
  T cell-derived lymphokines  
    and, 655
- Human cytomegalovirus  
  immunosuppression and, 282,  
    289-92  
  lymphocytes and, 281
- Human immunodeficiency virus  
  acquired immune deficiency  
    syndrome and, 574-77
- Human immunodeficiency virus  
  type 1, 309
- Human leukocyte antigen system  
  bone marrow transplantation  
    and, 45-47
- Human T-cell leukemia virus  
  type 1, 541-55  
  leukemogenesis and, 543  
  LTR function and, 548-51  
  pX proteins and, 544-48  
  transmission of, 542
- Human T-cell leukemia virus  
  type 2  
  hairy T-cell leukemia and,  
    542-43  
  LTR function and, 548-51
- Humoral immunity  
  vaccinia virus and, 306  
  virus infection and, 312-13
- Hybridoma Sp6  
   $\kappa$  gene of, 154
- Hydrogen channels  
  membrane depolarization and,  
    189-90
- Hydroxylamine  
  complement components and,  
    28
- Hydroxyllysine  
  complement C1q and, 23
- 5-Hydroxytryptamine  
  lymphocyte receptors for, 638
- Hypercalcemia  
  adult T-cell leukemia and,  
    541
- Hypergammaglobulinemic pur-  
  pura

- immature B cells and, 119
- Hyperimmunoglobulin E syndrome, 136-37
- Hypermutation
  - somatic immunoglobulin genes and, 169-70
- Hypersensitivity
  - delayed-type, 479
  - cimetidine and, 654
- Hyperthyroidism
  - adrenergic receptors in, 642
- Hypogammaglobulinemia
  - indomethacin and, 648
  - scid/scid* mice and, 370
- I
- Ibuprofen
  - interleukin-1 and, 75
- I-J determinants, 405-22
  - properties of, 410-14
- I-J phenotype
  - class-II genes and, 418
- I-J puzzle, 416-18
- I-J subregion, 407-10, 414-15
- Immune complexes
  - complement C1 activation and, 33-35
- Immune paralysis
  - polysaccharides and, 7
- Immune regulation
  - B-cell, 176-78
- Immune response
  - cimetidine and, 654
  - cyclic AMP and, 627-29
  - genetic control of, 8-11
- Immune system
  - cell adhesion receptors of, 223-44
  - neuropeptide hormones and, 633-36
- Immunodeficiency
  - bone marrow transplantation and, 48-51
  - murine models of, 367-91
  - organ system abnormalities and, 380-91
  - systemic autoimmunity and, 378-80
  - X-linked, 374-75
- Immunogenicity
  - electrical charge and, 6
- Immunoglobulin A
  - rheumatoid arthritis and, 120
- Immunoglobulin E
  - B-cell stimulatory factor-1 and, 443-47
  - hyperimmunoglobulin E syndrome and, 136-37
- Immunoglobulin G
  - B-cell stimulatory factor-1 and, 443-47
  - chemical cleavage of, 11
  - complement C1 and, 33
  - histamine and, 650
  - rheumatoid arthritis and, 120
- Immunoglobulin G antibodies
  - complement and, 116
  - differentiation of, 96
  - somatic mutation of, 86
- Immunoglobulin gene
  - somatic hypermutation of, 169-70
  - transgenic mice and, 151-71
- Immunoglobulin gene superfamily
  - evolution of, 591-92
- Immunoglobulin G rheumatoid factor, 109, 110, 114, 116
- rheumatoid arthritis and, 122
- Immunoglobulin joining reactions
  - chromosome translocation and, 259-67
- Immunoglobulin M
  - complement C1q and, 34
  - rheumatoid arthritis and, 120
- Immunoglobulin M antibodies
  - anti-DNA, 99
  - autoantigens and, 87
  - differentiation of, 96
  - pathogenicity of, 92
  - somatic mutation of, 86
- Immunoglobulin M paraprotein
  - Waldenström's macroglobulinemia and, 116
- Immunoglobulin M rheumatoid factor, 111, 114, 116
- Immunoglobulins
  - antigen-specific B cells and, 177
  - B cells and, 503
  - lipoygenase product formation and, 68
  - membrane transmembrane signaling and, 182-84
- Immunoglobulin synthesis
  - vasoactive intestinal peptide and, 636
- Immunoglobulin transgenes
  - immunoregulation of, 166-67
  - tissue-specific expression of, 152-58
- Immunosuppression
  - bone marrow transplantation and, 48-49
  - glucocorticoids and, 629
  - human cytomegalovirus and, 289-92
  - leukemogenesis and, 287
  - lymphocytic choriomeningitis virus, 292-97
  - measles virus and, 281-87
  - retroviruses and, 287-89
  - virus-induced, 279-99
- Immunotoxins
  - cancer and, 17
- Indomethacin
  - histamine release and, 647-48
  - plaque-forming cells and, 648
  - T suppressor cells and, 643
- Infection
  - chronic granulomatous disease and, 141
- Inflammatory response
  - complement cascade and, 377
  - lipid mediators of, 65
  - lipoygenases and, 67
  - myeloperoxidase system and, 141
- Influenza, 15
- Influenza virus
  - leukocyte adhesion deficiency disease and, 230
  - recombinant viruses and, 317-18
- Inositol lipid hydrolysis
  - calcium mobilization in B cells and, 185
- Inositol lipid metabolism
  - calcium mobilization and, 180
  - lipopolysaccharide and, 190
- Inositol phospholipid metabolism
  - B-cell stimulatory factor-1 and, 442
- Inositol triphosphate
  - B-cell activation and, 176
- Insulin
  - antigenic sites on, 481
  - B-cell activation and, 175
  - lymphocyte receptors for, 636-38
- Insulin receptors
  - protein kinases and, 180
- Interferon
  - adrenocorticotrophic hormone and, 634
- $\gamma$ -Interferon
  - arachidonic acid metabolites and, 75
  - B-cell activation and, 175
  - B-cell Ia expression and, 178
  - B cells and, 191
  - B-cell stimulatory factor-1 and, 433, 436-37, 443, 451
  - interleukin-2 and, 635, 643
  - leukotrienes and, 76
- Interleukin-1
  - adrenocorticotrophic hormone and, 634
  - arachidonic acid metabolism and, 76
  - B-cell stimulatory factor-1 and, 439-40
  - cyclic AMP agonists and, 629

- human cytomegalovirus and, 292
- lymphocyte receptors for, 622
- neutrophil adherence and, 132
- production of
  - lipoxigenase products and, 75-76
- Interleukin-2
  - B-cell stimulatory factor-1 and, 436-37, 448-50
  - cyclic AMP agonists and, 628
  - glucocorticoids and, 631
  - $\gamma$ -interferon and, 635, 643
  - lymphocyte receptors for, 622
  - production of
    - lipoxigenase products and, 75-76
  - T-cell receptor and, 466-68
  - T cells and, 288
- Interleukin-2 receptor
  - adult T-cell leukemia and, 541-42, 551-52, 554
  - histamine and, 650
  - prostaglandin  $E_2$  and, 645
- Interleukin-3
  - B-cell stimulatory factor-1 and, 452-53
  - histamine synthesis and, 655
- Interleukin-4
  - B-cell Ia expression and, 177
  - protein phosphorylation and, 190-91
  - See also B-cell stimulatory factor-1
- Interleukins
  - B-cell activation and, 175
- Intracranial pressure
  - Chediak-Higashi syndrome and, 135
- Isoproterenol
  - immune response and, 627
- J
  - Job's syndrome, 136-37
- K
  - Keratinocytes
    - Ia expression by, 370
- L
  - Lactoferrin
    - azurophil granules and, 132-33
    - thermal injury and, 134
  - Langerhan cells
    - Ia expression by, 370
  - Lectins
    - lipoxigenase pathway and, 68
  - Legionella pneumophila*
    - phagolysosomal fusion and, 139
  - Leukemia, 17
    - acute nonlymphoblastic, 54
    - adult T-cell, 541-42
    - development of, 553-55
    - interleukin-2 receptor and, 551-52, 554
    - bone marrow transplantation and, 53-58
    - chromosome translocation and, 272-73
    - chronic lymphatic
      - rheumatoid factor and, 116-17
    - chronic lymphocytic
      - chromosome translocation in, 259-60
    - chronic myelogenous, 55, 57
      - chromosome translocation and, 271-72
      - Philadelphia chromosome and, 253
    - hairly T-cell, 542-43
    - human cytomegalovirus and, 289
    - human T-cell
      - CD3 and, 523-24
    - retroviruses and, 320
  - Leukemogenesis
    - immunosuppression and, 287
    - viruses and, 543-44
  - Leukocyte adhesion deficiency
    - disease, 225, 228-30
  - Leukocytes
    - activation of
      - leukotriene  $B_4$  and, 69
    - iC3b receptor deficiency and, 130-32
    - LFA-1 and, 225
    - 5-lipoxygenase in, 65
  - Leukocytosis
    - chronic granulomatous disease and, 141
    - neutrophilic
      - iC3b receptor deficiency and, 130
  - Leukotriene  $B_4$ , 67
  - Leukotriene  $B_4$ 
    - lymphocyte receptors for, 642-44
    - sources of, 68-71
  - Leukotrienes
    - conjugated double bonds of, 67
    - inflammatory response and, 141
    - mononuclear phagocytes and, 128
    - neutrophils and, 128
    - thromboxane formation and, 77
  - Lipids
    - antigens specific to, 6
  - Lipocortin
    - glucocorticoids and, 632
    - glycosylation-inhibitory factor and, 630
    - lipid mediators of inflammation and, 78
    - phospholipase inhibition and, 630
  - Lipomodulin
    - I-J molecules and, 421
  - Lipopolysaccharide
    - B-cell activation and, 175
    - impaired responses to, 375-77
    - protein kinase C and, 190
  - Lipoxins, 67, 77
  - Lipoxygenase pathway, 65-79
    - arachidonic acid and, 65-68
  - Lipoxygenase products
    - cholesterol deposition and, 79
    - inflammatory responses and, 67
    - interleukins and, 74-76
    - lipocortin and, 630
    - platelet activating factor and, 76-77
    - thromboxane  $A_2$  and, 76-77
  - 5-Lipoxygenases
    - sources of, 68
  - Listeria monocytogenes*
    - acid/scid mice and, 372
  - Liver abscess
    - chronic granulomatous disease and, 141
  - Liver disease
    - hepatitis B virus and, 313
  - Low-density lipoprotein
    - lymphocytes and, 79
  - Lung abscess
    - chronic granulomatous disease and, 141
  - Lymphadenitis
    - chronic granulomatous disease and, 141
  - Lymphadenopathy
    - chronic granulomatous disease and, 141
  - Lymphocyte chemoattractant
    - factor, 650
  - Lymphocyte function-associated
    - antigens, 223-44
    - T-cell function and, 521
  - Lymphocyte hormone receptors, 621-57
  - Lymphocytes
    - adrenocorticotrophic hormone receptors on, 634
    - high endothelial cell recognition mechanisms of, 209-17
    - human cytomegalovirus and, 289-92

- hyperimmunoglobulin E syndrome and, 136  
 leukotriene B<sub>4</sub> and, 68-71  
 5-lipoxygenase products and, 76  
 low-density lipoprotein and, 79  
 lymphocytic choriomeningitis virus and, 292-97  
 malignant transformation of, 117  
 measles virus and, 283-87  
 recirculation of, 201-19  
 characteristics of, 202-5  
 high endothelial cell venules and, 205-8  
 retroviruses and, 287-89  
 See also B cells; T cells  
 Lymphocyte-virus interactions, 279-99  
 Lymphocytic choriomeningitis virus  
   immunosuppression and, 292-97  
   lymphocytes and, 281  
 Lymphoid malignancy  
   rheumatoid factor and, 116-18  
 Lymphokines  
   arachidonic acid metabolism and, 72  
   glucocorticoids and, 633  
   lymphocyte receptors for, 622  
 Lymphoma, 17  
   B-cell  
     bone marrow transplantation and, 117-18  
     Sjogren's syndrome and, 119  
   Burkitt  
     acquired immune deficiency syndrome and, 258-59  
     chromosome translocations in, 254-55  
     *c-myc* gene and, 256  
     sporadic vs. endemic, 257-58  
     chromosome translocation and, 272-73  
     diffuse B-cell  
       chromosome translocation in, 259-60  
     human cytomegalovirus and, 289  
 Lymphomagenesis  
   hairless mice and, 384-85  
 Lysine  
   experimental allergic encephalomyelitis and, 16  
 Lysosomal enzyme release  
   leukotriene B<sub>4</sub> and, 69  
 Lysozyme, 7, 10, 14  
   MHC class II-restricted T cells and, 478  
   T-cell responses to, 492-93  
   thermal injury and, 134  
 M  
 Macroglobulinemia  
   autoantibodies and, 91  
   Waldenstrom's, 93  
   rheumatoid factor and, 116-17  
 Macrophages  
   athymic mice and, 369  
   B-cell stimulatory factor-1 and, 429, 438, 453  
   glucocorticoids and, 631  
   glycosylation-inhibiting factor and, 421  
   Ia expression on  
     5-hydroxytryptamine and, 638  
   LFA-1 and, 225  
   lipid metabolism in  
     regulation of, 79  
   lipomodulin and, 421  
   platelet activating factor production in, 77  
   prostaglandin E<sub>2</sub> and, 644, 647  
   respiratory burst in, 139  
   slow-reacting substances and, 71-72  
 Major histocompatibility complex  
   bone marrow transplantation and, 44  
   class-II  
     B-cell stimulatory factor-1 and, 429, 453  
   T-cell antigen receptor and, 334-35, 477, 503, 512-15  
   T cells and, 585  
 Major histocompatibility complex antigens  
   thymic stroma and, 339  
 Major histocompatibility complex restriction, 331, 477, 512  
   extrathymic influences on, 347-48  
 Malaria, 15  
   chromosome translocation and, 258  
   immune system and, 258  
 Mannose-6-phosphate  
   lymphocyte adhesion and, 209  
 Mast cell growth factor-2  
   B-cell stimulatory factor-1 and, 432, 452-53  
 Mast cells  
   histamine and, 648-49  
   leukotriene B<sub>4</sub> and, 68  
   5-lipoxygenase in, 65  
   5-lipoxygenase products of, 68  
   slow-reacting substances and, 71  
 Measles virus  
   immunosuppression and, 281-87  
   lymphocytes and, 281  
 Megakaryocytes  
   B-cell stimulatory factor-1 and, 429, 453-54  
 Membrane immunoglobulin  
   transmembrane signaling and, 182-84  
 Meningitis  
   chronic granulomatous disease and, 141  
 Metallothionein promoter  
   transgenic mice and, 152  
 Methotrexate  
   bone marrow transplantation and, 57  
 p-Methylsulfonylfluoride  
   complement C1 and, 31  
 Methylxanthines  
   cytotoxic T cells and, 640  
 Mice  
   congenitally asplenic dominant hemimelia, 380-81  
   congenitally athymic nude, 368-70  
   diabetes-obesity mutant, 386-87  
   hairless  
     immunodeficiency in, 384-85  
   hypopituitary dwarf, 385-86  
   motheaten, 372-74  
   neurological-neuromuscular mutant, 386-88  
   osteopetrosis mutant, 389-91  
   pigmentation mutations in, 381-84  
   *scid/scid*, 370-72  
   See also Transgenic mice  
 Microphthalmia, 389  
 Mitogenesis  
   lipoxygenase products and, 74  
 Mixed cryoglobulinemia  
   rheumatoid factor and, 119  
 Mixed leukocyte culture  
   bone marrow transplantation and, 44  
 Mixed lymphocyte reactions  
   I-J determinants and, 414  
 Monocytes  
   B-cell stimulatory factor-1 and, 454  
   glucocorticoids and, 631  
   histamine receptors on, 649  
   human cytomegalovirus and, 289-92  
   interleukin-1 formation in, 75



- leukotriene B<sub>4</sub> and, 68-69, 643
- LFA-1 antigen on, 130
- 5-lipoxygenase products of, 68
- 15-lipoxygenase products of, 77
- measles virus and, 284
- Mol antigen on, 130
- prostaglandin E<sub>2</sub> and, 644
- respiratory burst in, 139
- somatostatin receptors on, 635
- T helper cells and, 115
- Monokines
  - lymphocyte receptors for, 622
- Mononucleosis
  - human cytomegalovirus and, 289-92
- Motor end-plate disease, 388
- Mucositis
  - iC3b receptor deficiency and, 130
- Multiple myeloma
  - chromosome translocation and, 259-60
  - monoclonal immunoglobulin molecules and, 98
- Multiple sclerosis, 15-16
- Murine leukemia virus
  - envelope glycoproteins of, 309
  - lymphocyte proliferation and, 287
  - recombinant viruses and, 320
  - scid/scid mice and, 370-71
- Murine mammary tumor virus, 377
- Mutation
  - murine pigmentation, 381-84
  - somatic
    - autoantibody formation and, 94-102
    - autoimmunity and, 85-102
- Myasthenia gravis
  - anti-acetylcholine receptor antibodies in, 89
  - antigen-specific T helper cells and, 95
- Mycobacterium tuberculosis*
  - phagolysosomal fusion and, 139
- Myeloid precursor cells
  - LFA-1 on, 225
- Myeloma
  - autoantibodies and, 91
  - DNA-binding, 98-99
- Myeloma MOPC-167
  - phosphorylcholine and, 154
- Myeloperoxidase deficiency, 144
- Myeloperoxidase system
  - inflammatory response and, 141
- Myoglobin
  - antigenic sites on, 481
  - MHC class II-restricted T cells and, 478
- Myosin
  - poly-DL-alanylation and, 12
- N
- NADPH
  - chronic granulomatous disease and, 143-44
- Naloxone
  - opiate receptors and, 634
- Natural killer cell-mediated cytotoxicity
  - LFA-1 and, 226
- Natural killer cells
  - anti-LFA-1 antibodies and, 521
  - athymic mice and, 369
  - cholinergic agonists and, 639
  - cyclic AMP agonists and, 627
  - endorphin and, 634
  - glucocorticoids and, 631
  - histamine and, 650, 652
  - insulin and, 637
  - leukotriene B<sub>4</sub> and, 643
  - measles virus and, 284
  - motheaten mice and, 372
  - prostaglandin E<sub>2</sub> and, 645
  - vasoactive intestinal peptide and, 636
- Neuraminidase
  - lymphocyte migration and, 209
- Neuropathy
  - peripheral
    - Chediak-Higashi syndrome and, 135
- Neuropeptide hormones
  - immune system and, 633-36
- Neutropenia
  - Chediak-Higashi syndrome and, 135
- Neutrophils
  - Chediak-Higashi syndrome and, 135-36
  - chemotactic receptors of, 128-29
  - chronic granulomatous disease and, 142
  - diapedesis and, 128, 132
  - hyperimmunoglobulin E syndrome and, 136-37
  - iC3b receptor deficiency and, 130-32
  - leukotriene B<sub>4</sub> and, 68-69
  - LFA-1 antigen on, 130
  - 5-lipoxygenase products of, 68
  - localized juvenile periodontitis and, 137-38
- margination of, 127-28
- maturation of
  - granule deficiency and, 132-35
- Mol antigen on, 130
- platelet activating factor production in, 77
- respiratory burst in, 139
- Nifedipine
  - plasma membrane and, 185-86
- Nitrophenylguanidinobenzoate
  - complement C1 and, 33
- Nordihydroguaric acid
  - DNA synthesis and, 70
- Nordimiprit
  - lymphocytes and, 650
- Nucleosides
  - antigens specific to, 6
- Nystagmus
  - Chediak-Higashi syndrome and, 135
- O
- Organ transplantation
  - human cytomegalovirus and, 289
- Orthopoxviruses, 307
- Osteomyelitis
  - chronic granulomatous disease and, 141
- Osteopetrosis, 389-91
- Osteosclerosis, 390-91
- Otitis
  - hyperimmunoglobulin E syndrome and, 136
  - iC3b receptor deficiency and, 130
- Ovalbumin
  - antigenic sites on, 481
  - T-cell responses to, 488
- Oxidative metabolism
  - chronic granulomatous disease and, 141
  - thermal injury and, 134
- Oxytocin
  - lymphocyte receptors for, 635
- P
- Paraformaldehyde
  - antigen processing and, 480
- Peptides
  - antigenic potency of, 484-85
  - antigens specific to, 6
- Periodontitis
  - iC3b receptor deficiency and, 130
  - localized juvenile, 137-38
- Phagocytes
  - disorders of, 127-44

- Phagocytic cells  
 antimicrobial systems of, 138-41  
   disorders of, 141-44  
   microbicidal mechanisms of, 138  
 Phagocytosis  
   myeloperoxidase deficiency and, 144  
 Phenylalanine, 9  
 Philadelphia chromosome  
   chronic myelogenous leukemia and, 253  
 Phorbol esters  
   lymphocyte aggregation and, 231  
 Phorbol myristate acetate  
   B-cell activation and, 176  
   B-cell stimulatory factor-1 and, 429-30  
   protein kinase C and, 180-81  
 Phosphatidylcholine  
   inflammation and, 65  
 Phosphatidylinositol 4,5-bisphosphate  
   actin polymerization and, 129  
   ligand binding and, 181  
 Phosphatidylinositol metabolism  
   anti-immunoglobulin antibodies and, 182  
 Phosphodiesterase  
   indomethacin and, 648  
   theophylline and, 627  
 Phosphoinositide metabolism  
   induction of, 181  
 Phospholipase A<sub>2</sub>  
   lipocortin and, 78, 630  
 Phospholipase C  
   arachidonic acid and, 78  
   calcium mobilization in B cells and, 185  
   5-hydroxytryptamine and, 638  
   lipoxins and, 77  
   membrane depolarization and, 188  
   phosphatidylinositol 4,5-bisphosphate and, 181  
   as second messenger, 625  
 Phospholipid metabolism  
   membrane immunoglobulin and, 182-84  
 Phospholipids  
   anti-DNA antibodies and, 97  
   protein kinases and, 179  
 Phosphorylation  
   interleukin-4 and, 190-91  
   proteins and, 178-79  
 Phosphorylcholine  
   myeloma MOPC-167 and, 154  
   myeloma proteins and, 99  
 Photophobia  
   Chediak-Higashi syndrome and, 135  
 Planar membranes  
   T-cell recognition of antigen in, 464-73  
 Plaque-forming cells  
   cholera toxin and, 629  
   cyclic AMP agonists and, 627  
   histamine and, 650  
   indomethacin and, 648  
   opiate receptors and, 634  
 Plasmacytoma, 17  
   chromosome translocation and, 255, 261-63, 267-68  
 Plasmin  
   complement C1s and, 25  
 Plasminogen  
   activation of  
     streptokinase and, 36  
*Plasmodium falciparum*  
   T cells and, 258  
 Platelet activating factor  
   lipoxygenase products and, 76-77  
 Platelets  
   12-lipoxygenase in, 65  
*Pneumocystis carinii*  
   scid/scid mice and, 370  
 Pneumonia  
   chronic granulomatous disease and, 141  
   hyperimmunoglobulin E syndrome and, 136  
 Polyalanine, 7, 9  
 Polyamino acids, 2  
   antigenic specificity of, 6  
 Polyarginine, 2  
 Polyaspartic acid, 2  
 Polycarboxybenzoxyllysine, 4  
 Polycyclohexylalanine, 2  
 Polyhistidine, 2  
 Polyhydroxyproline, 2  
 Poly-L-lysine  
   T-cell epitopes and, 482  
 Poly-L-phenylalanine, 4  
 Poly-L-tyrosine, 2  
 Polylysine, 2-3  
 Polymorphonuclear leukocytes  
   leukotriene B<sub>4</sub> and, 70  
   15-lipoxygenase products in, 77  
 Polyornithine, 3  
 Poly-p-amino-L-phenylalanine, 2  
 Poly-p-aminophenylalanine, 5  
 Polypyrrolone, 2, 4  
 Polysaccharides  
   immune paralysis and, 7  
 Polyserine, 2  
 Polytryptophan, 2  
 Polytyrosine, 5  
 Potassium channels  
   membrane depolarization and, 189  
 Poxviruses  
   biology of, 307-8  
 L-Proline  
   immunogenicity of, 7  
 Pro-opiomelanocortin  
   adrenocorticotrophic hormone and, 634  
 Prostaglandin  
   cyclooxygenase pathway and, 68  
   immune response and, 627-29  
   inflammatory response and, 141  
   thymocytes and, 646  
 Prostaglandin E<sub>2</sub>  
   activation of, 186-88  
   lymphocyte receptors for, 644-48  
 Protein kinase C  
   activation of, 186-88  
   B-cell stimulatory factor-1 and, 442  
   diacylglycerol and, 180-81, 520  
   lipopolysaccharide and, 190  
   membrane depolarization and, 188-90  
 Protein kinases  
   cell metabolism and, 179  
   epidermal growth factor receptors and, 180  
   indomethacin and, 648  
   insulin receptors and, 180  
   second messenger-dependent, 178-79  
 Pulmonary disease  
   measles and, 283  
 Pyridoxal  
   antigens specific to, 6  
 3-Quinuclidinyl benzilate  
   lymphocyte receptors for, 638  
 R  
 Rabies virus  
   recombinant viruses and, 319  
 Ranitidine  
   T suppressor cells and, 654  
 Recombinant DNA technology  
   virus expression vectors and, 305  
 Recombinant viruses  
   formation of, 308-9  
   hepatitis B virus and, 316  
   herpes simplex virus and, 317  
   influenza virus and, 317-18  
   murine leukemia virus and, 320  
   protein expression by, 309  
   rabies virus and, 319

- respiratory syncytial virus  
and, 318-19  
vesicular stomatitis virus and,  
319
- Respiratory syncytial virus  
recombinant viruses and, 318-  
19
- Restriction endonuclease  
structure of, 30
- Retroviruses  
acquired immune deficiency  
syndrome and, 320  
host range of, 306  
immunosuppression and, 287-  
89  
leukemia and, 320  
LTR sequences of, 548  
tumorigenesis and, 543-44
- Rheumatoid arthritis, 94, 109  
indomethacin and, 648  
rheumatoid factor and, 119-22
- Rheumatoid factor, 109-23  
autoimmune disease and, 118-  
22  
derivation of, 93-94  
lymphoid malignancies and,  
116-18  
synthesis of  
genetic control of, 109-14  
induction of, 114-16
- RNase, 3-4
- S
- Seizures  
Chediak-Higashi syndrome  
and, 135
- Septicemia  
chronic granulomatous disease  
and, 141
- Serotonin  
arachidonic acid metabolism  
and, 72  
lymphocyte receptors for, 638
- Severe combined immune de-  
ficiency, 370-72  
adenosine deaminase de-  
ficiency and, 639  
bone marrow transplantation  
and, 44, 49-50
- Sindbis virus  
structural proteins of, 320
- Sinusitis  
hyperimmunoglobulin E syn-  
drome and, 136
- Sjogren's syndrome  
rheumatoid factor and, 119
- Slow-reacting substances, 71-74
- Smallpox, 306-7
- Sodium channels  
membrane depolarization and,  
189-90
- Somatic hypermutation  
immunoglobulin genes and,  
169-70
- Somatic mutation  
autoantibody formation and,  
94-102  
autoimmunity and, 85-102
- Somatostatin  
insulin and, 636
- Somatostatin  
lymphocyte receptors for, 635
- Staphylococcal nuclease  
antigenic sites on, 481
- Staphylococcus albus*  
interleukin-1 formation and,  
75
- Staphylococcus aureus*  
chronic granulomatous disease  
and, 141
- Streptokinase  
plasminogen activation and, 36
- Subacute bacterial endocarditis  
rheumatoid factor and, 119
- Substance P  
lymphocyte receptors for,  
635-36
- Sugars  
antigens specific to, 6
- Sulfinidoleukotrienes, 67
- Suppressor T cells  
See T suppressor cells
- SV40  
host range of, 306
- Systemic lupus erythematosus  
adenosine and, 640  
anti-DNA antibodies in, 89,  
96-99
- T
- T-cell antigen receptor, 330-38,  
503-29  
antibodies to, 509-12  
CD3 complex and, 515-18  
chromosome translocation  
and, 610-13  
expression in thymus, 336-38  
genes of, 585-613  
identification of, 504-5  
interleukin-2 and, 466-68  
intrathymic differentiation  
and, 526-29  
major histocompatibility com-  
plex and, 477, 503, 512-  
15  
malignancies and, 608-10  
molecular characteristics of,  
586-608  
molecular genetics of, 508-9  
ontogeny of, 335-36  
proliferative disorders and,  
608-10  
structure of, 505-7  
T cell-B cell interactions  
B-cell stimulatory factor-1  
and, 451-52
- T-cell epitopes  
identification of, 481-82  
models for, 485-87  
primary amino acid sequences  
of, 479-81  
size of, 482-84  
structure of, 477-97
- T-cell growth factor-2  
B-cell stimulatory factor-1  
and, 432, 447-48, 452-  
53
- T-cell mediated cytotoxicity  
LFA-1 and, 226
- T-cell neoplasms  
chromosome translocations in,  
254-59
- T-cell receptor genes, 506-7
- T-cell replacing factor  
dibutyryl cyclic AMP and,  
629
- T cells  
accessory molecules and, 520-  
23  
acquired immune deficiency  
syndrome and, 575-76  
activation of  
antigen-presenting cells  
and, 523  
CD3 complex and, 518-20  
adenosine and, 639-41  
adrenocorticotrophic hormone  
and, 634  
antigen recognition by, 461-  
73, 514-15  
autoimmune response and, 95  
B-cell activation and, 176  
B-cell stimulatory factor-1  
and, 447-50  
CD2 and, 237-39, 521-22  
cyclic AMP agonists and,  
628-29  
function of  
LFA-3 and, 243  
glucocorticoids and, 630-33  
glycosylation-inhibiting factor  
and, 421  
histamine and, 652-55  
histamine receptors on, 649  
I-J determinants and, 411-13  
insulin receptors on, 636-38  
interleukin-2 and, 288  
leukotriene B<sub>4</sub> and, 68-71  
LFA-1 antigen on, 130  
LFA-1 surface sites on, 225  
lipomodulin and, 421  
major histocompatibility com-  
plex and, 585  
maturation of, 325-57

- measles virus and, 283-87  
 muscarinic cholinergic receptors on, 639  
 permeability of, 190  
 rheumatoid arthritis and, 120-22  
 severe combined immune deficiency and, 370-72  
 subsets of, 621-22  
 substance P receptors on, 635-36  
 thymopoietin and, 370  
 vasoactive intestinal peptide and, 636  
 See also Cytotoxic T cells; T helper cells; T suppressor cells
- Tetanus-antitetanus immune complexes  
 complement C1 and, 35
- Tetanus toxoid, 14  
 leukocyte adhesion deficiency disease and, 230
- T helper cells  
 activated B cells and, 115  
 adult T-cell leukemia and, 541-42  
 anti-CD3 antibodies and, 519  
 B cells and, 177  
 histamine and, 652-53  
 leukotriene B<sub>4</sub> and, 643-44  
 LFA-1 and, 226  
 malaria and, 258  
 measles virus and, 284  
 planar membranes and, 465-68  
 receptors on, 462
- Theophylline  
 phosphodiesterase and, 627  
 T cell rosetting and, 640
- Thermal injury  
 neutrophil activation and, 134
- Thromboxane A<sub>2</sub>  
 cyclooxygenase pathway and, 68  
 lipooxygenase products and, 76-77  
 macrophages and, 72
- Thymic colonization, 348-52
- Thymic nurse cell complex, 340-41
- Thymic ontogeny, 341-43, 592-93
- Thymocytes  
 adrenocorticotrophic hormone receptors on, 634  
 B-cell stimulatory factor-1 and, 450  
 CD2 and, 237-39  
 development of  
 CD4 and CD8 and, 563  
 glucocorticoids and, 630  
 precursor-progeny relationships in, 352-56  
 prostaglandin and, 646  
 subpopulations of, 326-30  
 Thymopoietin, 624  
 T-cell differentiation and, 370  
 Thymulin, 624  
 Thymus  
 functions of, 345-48  
 immature T cells in  
 proliferation of, 242  
 microenvironment of, 338-45  
 T-cell receptor expression in, 336-38
- Thyroiditis  
 antigen-specific T helper cells and, 95  
 experimental autoimmune, 91
- Thyrotropin  
 lymphocyte receptors for, 635
- Total body irradiation  
 bone marrow transplantation and, 51
- Toxoplasma gondii*  
 phagolysosomal fusion and, 139
- Transgenes  
 See Immunoglobulin transgenes
- Transgenic mice  
 κ genes of, 152-54  
 allelic exclusion of, 159-62  
 isotypic exclusion of, 164-65  
 somatic hypermutation of, 169-70  
 λ genes of  
 isotypic exclusion of, 164-65  
 μ genes of, 154-56  
 allelic exclusion of, 162-64  
 immunoglobulin, 151-71
- Transmembrane signaling, 175-93  
 B-cell receptors and, 182-91
- Trypanosoma cruzi*  
 phagolysosomal fusion and, 139
- T suppressor cells  
 antierythrocyte antibodies and, 101  
 autoantibodies and, 101  
 cimetidine and, 654  
 cyclic AMP and, 626  
 experimental allergic encephalomyelitis and, 16  
 hemolytic anemia and, 101  
 histamine and, 651-52  
 I-J determinants and, 411  
 leukotriene B<sub>4</sub> and, 643-44  
 measles virus and, 284  
 prostaglandin E<sub>2</sub> and, 646  
 ranitidine and, 654  
 substance P and, 636
- Tuberculin antigen  
 measles virus and, 284
- Tuberculosis  
 measles and, 283
- Tumor necrosis factor  
 neutrophil adherence and, 132
- Tyrosine, 9  
 experimental allergic encephalomyelitis and, 16
- ## V
- Vaccines  
 synthetic, 14-15
- Vaccinia virus  
 biology of, 307-8  
 genetic engineering and, 306  
 protein expression by, 309  
 thymidine kinase gene of, 308-9
- Variola virus, 307
- Vasoactive intestinal peptide  
 lymphocyte migration and, 209  
 lymphocyte receptors for, 636
- Vesicular stomatitis virus  
 envelope glycoproteins of, 309  
 recombinant viruses and, 319
- Viral antigens  
 autoreactivity of, 102
- Viruses  
 leukemogenesis and, 543-44  
 MHC class I-restricted T cells and, 478  
 neutralizing antibodies and, 312  
 recombinant  
 formation of, 308-9  
 protein expression by, 309  
 See also specific virus
- Virus expression vectors, 305-22  
 types of, 305-6
- Virus-lymphocyte interactions, 279-99
- Vitamin B-12 binding protein  
 azurophilic granules and, 132-33
- ## W
- Waldenström's macroglobulinemia, 93  
 rheumatoid factor and, 116-17
- Wiskott-Aldrich syndrome, 375  
 bone marrow transplantation and, 44, 48-49
- ## Z
- Zymosan  
 lipooxygenase pathway and, 68

